Return to homepagePandemic Pact

COVID19AM: Clinical development and production of vilobelimab as a first-in-class anti-C5 antibody for the treatment of critically ill COVID-19 patients (VILO-COVID)

  • Funded by Federal Ministry of Research, Technology and Space (BMFTR)
  • Total publications:2 publications

Grant number: 16LW0113

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2021
    2023

  • Known Financial Commitments (USD)

    $38,573,185.94

  • Funder

    Federal Ministry of Research, Technology and Space (BMFTR)

  • Research Location

    Germany

  • Lead Research Institution

    InflaRx GmbH

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

2 Publications linked via Europe PMC

Last Updated:3 days ago

View all publications at Europe PMC

Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients.

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.